Patents Assigned to CRINETICS PHARMACEUTICALS, INC.
-
Patent number: 11957674Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: January 25, 2022Date of Patent: April 16, 2024Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
-
Patent number: 11834462Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: April 6, 2022Date of Patent: December 5, 2023Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
-
Patent number: 11773076Abstract: Described herein are crystalline forms of 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide, uses of such crystalline forms in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a somatostatin modulator compound.Type: GrantFiled: February 16, 2022Date of Patent: October 3, 2023Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Yuxin Zhao, Jayachandra P. Reddy, Lauren Maceachern, Samer Kahwaji, Evans Monyoncho, Peter Mueller
-
Patent number: 11608335Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: February 11, 2019Date of Patent: March 21, 2023Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Shimiao Wang, Yunfei Zhu
-
Patent number: 11566015Abstract: Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.Type: GrantFiled: February 8, 2021Date of Patent: January 31, 2023Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
-
Patent number: 11479540Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: August 10, 2020Date of Patent: October 25, 2022Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Yunfei Zhu, Shimiao Wang, Mi Chen, Joseph Pontillo
-
Patent number: 11414397Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: October 26, 2020Date of Patent: August 16, 2022Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Sangdon Han, Sun Hee Kim, Shimiao Wang, Yunfei Zhu
-
Patent number: 11266641Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: September 7, 2021Date of Patent: March 8, 2022Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
-
Patent number: 11186590Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: May 19, 2020Date of Patent: November 30, 2021Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
-
Patent number: 11072598Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: September 16, 2019Date of Patent: July 27, 2021Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
-
Patent number: 11028068Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: July 24, 2018Date of Patent: June 8, 2021Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Yunfei Zhu, Shimiao Wang, Sangdon Han, Sun Hee Kim
-
Patent number: 10981894Abstract: Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.Type: GrantFiled: July 16, 2020Date of Patent: April 20, 2021Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
-
Patent number: 10889561Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: October 3, 2019Date of Patent: January 12, 2021Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jayachandra P. Reddy, Mahmoud Mirmehrabi
-
Patent number: 10875839Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: December 12, 2019Date of Patent: December 29, 2020Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Shimiao Wang, Yunfei Zhu
-
Patent number: 10766877Abstract: Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.Type: GrantFiled: December 13, 2019Date of Patent: September 8, 2020Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao
-
Patent number: 10696689Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: September 17, 2019Date of Patent: June 30, 2020Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
-
Patent number: 10604507Abstract: Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.Type: GrantFiled: August 27, 2019Date of Patent: March 31, 2020Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
-
Patent number: 10597377Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: May 8, 2019Date of Patent: March 24, 2020Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Shimiao Wang, Yunfei Zhu
-
Patent number: 10562884Abstract: Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.Type: GrantFiled: June 5, 2019Date of Patent: February 18, 2020Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
-
Patent number: 10464918Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: January 16, 2019Date of Patent: November 5, 2019Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jayachandra P. Reddy, Mahmoud Mirmehrabi, Madhukar Kota, Uttam Dash
